A73 COST-EFFECTIVENESS OF INFLIXIMAB BIOSIMILAR COMPARED TO ORIGINATOR INFLIXIMAB FOR THE MANAGEMENT OF CROHN’S DISEASE

BACKGROUND: Originator infliximab (marketed as Remicade) was the first biological therapy approved in patients with Crohn’s Disease (CD), and has been proven to be effective for the induction and maintenance of remission in patients with moderate-to-severe disease. Due to its recent patent expiry, a...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Can Assoc Gastroenterol
Asıl Yazarlar: Beilman, C L, Ma, C, McCabe, C, Fedorak, R, Halloran, B P
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2018
Konular:
Paper Sessions
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6508372/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy009.073
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller